MedTrace Logo

CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases

NCT04662294 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2021-11-04

No results posted yet for this study

Summary

A Study of CD 70 CAR T for patients with CD70 positive malignant hematologic diseases

Conditions

Interventions

BIOLOGICAL

CD70 CAR T-cells

Each subject receive CD70 CAR T-cells by intravenous infusion

Sponsors & Collaborators

  • Yake Biotechnology Ltd.

    collaborator INDUSTRY

  • Zhejiang University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-18
Primary Completion
2024-01-15
Completion
2027-01-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04662294 on ClinicalTrials.gov